PlatformQ Health

Press Releases

Boston, MA (PRWEB) October 12, 2017 – The third in a series of online programs focusing on clinical and non-clinical topics for Urologists will air live October 16, 2017 at 1:00 p.m. EDT on UroCareLive. The program, Establishing an Advanced Bladder Cancer Clinic, will include information on the latest clinical guidelines in bladder cancer, updates on promising clinical trials, and tactical information to help urologists and practice administrators set up and maintain an advanced bladder clinic. Topics discussed will include:

  • • Highlights of Non-Muscle Invasive Bladder Cancer’s (NMIBC) newest guidelines
  • • Unmet needs in NMIBC
  • • Promising trials and new therapeutics
  • • Highlights of Muscle-Invasive and Metastatic Bladder Cancer’s (MIBC) newest guidelines
  • • Review of immuno-oncologics, including MOA, indications and management
  • • Promising trials and combinations
  • • Initiating an advanced bladder cancer clinic

Expert faculty for the program will include:

  • • Dr. Neal D. Shore, MD, FACS, President, LUGPA (Large Urology Group Practice Association), Carolina Urologic Research Center/Atlantic Urology Clinics, Myrtle Beach, SC
  • • Dr. Noah M. Hahn, MD, Associate Professor of Medicine, Department of Oncology and Urology, and Director, Medical Oncology Bladder Cancer Program at Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center
  • • Dr. Ashish M. Kamat, MD, MBBS, FACS, Professor of Urology, Wayne B. Duddlesten Professor in Cancer Research, Division of Surgery at The University of Texas MD Anderson Cancer Center- Dr. Jonathan Henderson, MD, Secretary, LUGPA (Large Urology Group Practice Association), CEO, Regional Urology, LLC, Shreveport, Louisiana

Participants are able to submit questions for the expert panel prior to and during the live broadcast, allowing presenters to respond in real time, combining the benefits of in-person interactive education with the convenience of digital access. Questions may be submitted here.

Three other previously-recorded educational programs are also available for viewing on UroCareLive, spanning a wide range of topics, including an accredited program discussing personalized care for metastatic bladder cancer, and two practice management-focused programs.

The Future of Urology Practices: Independent, Hospital-Owned or Private Equity aired live August 31, 2017 and is now available for viewing at no cost, focusing on some of the topics that are important to the business of medicine and practice management, including:

  • • Update and impact of healthcare reform and policy
  • • Changes in Part B reimbursement: point/counterpoint- Medicare Access and CHIP Reauthorization Act (MACRA)
  • • Financial aspects of practice management, like recruitment of Urologists and the changing labor dynamics in the Urology workplace

New Horizons in Personalized Care for Metastatic Bladder Cancer originally aired on PlatformQ Health’s Oncology education platform, OMedLive, and is available as a one-hour accredited CME program. Produced in collaboration with the Bladder Cancer Advocacy Network (BCAN) and faculty from Mount Sinai School of Medicine and the UNC Lineberger Comprehensive Cancer center, this accredited program goes in depth about:

  • • The latest clinical data of new and emerging agents
  • • Immunotherapy
  • • Chemotherapy selections- Multimodal therapies
  • • Clinical trials for bladder cancer
  • • Multidisciplinary care

UroCareLive’s inaugural program, Developing an Effective Advanced Prostate Cancer Clinic, is also available for clinicians, discussing:

  • • Operational issues for Advanced Prostate Cancer Clinics
  • • Improving physician organizational development
  • • Providing patient access to more advanced therapies (existing and emerging therapies)
  • • Generating new revenue sources
  • • Retaining patient market share

For more information about UroCareLive and LUGPA’s Virtual Crossfire Event Series, visit UroCareLive.com or LUGPA.org.

About LUGPA

LUGPA currently represents more than 25 percent of the nation’s urology practices, comprising more than 2,300 members, who account for approximately 30 percent of urologic care in the United States. The Association is committed to providing the best resources to its member practices through advocacy, research, data collection and benchmarking efforts. LUGPA advocates for independent urology practices by promoting quality clinical outcomes, fostering new opportunities and improving advocacy in legislative and regulatory arenas.

About PlatformQ Health

PlatformQ Health is the leading provider of live, online medical education events, operating 16 therapeutically aligned learning channels dedicated to providing clinicians, patients, caregivers, advocates and administrators rigorous, outcomes-centric education aimed at improving patient care. The company’s unique education platform allows physicians and other healthcare professionals to connect online from anywhere, to learn about the latest treatments options, and engage in real-time discussion with scientific, research and patient care experts.

UroCareLive offers live streaming video lectures, panel discussions and case presentations, as well as interactive activities such as real-time questions and answer sessions with top faculty and other participants.

Boston, MA (PRWEB) September 12, 2017 – Joslin Diabetes Center, in partnership with DiabetesSeriesLive, will present a series of live-online CME programs on the evolution of insulin replacement therapy, focusing on new perspectives, evolving technologies, and clinical applications. This educational series is available to clinicians at no cost.

Recent, exciting advances in both the development of pharmacologic tools and technical devices aimed at replicating the normal secretion of insulin in people with diabetes have brought us considerably closer to ideally mimicking natural insulin secretory patterns. However, for these new advances to be optimally utilized, clinicians must be familiar with their indications, usage parameters, and approaches to troubleshooting should the need arise.

“We are excited to present this four-part series of educational programs from the leaders in the space to keep clinicians up to date on the newer insulins and devices,” said Robert Rosenbloom, President and CEO of PlatformQ Health. “It is our hope that the education clinicians access on DiabetesSeriesLive will stimulate learners to think about what they can and should do in their own office setting versus outsource to regional specialty centers, making quality care available to a larger number of patients with diabetes.”

The first one-hour program will air live online Thursday, September 14, 2017 from 3:00-4:00pm ET on DiabetesSeriesLive.com. Richard S. Beaser, MD and Alissa R Segal, PharmD will present Insulin Options for Diabetes: Update on the Evolution. This free online CME session will identify clinically relevant pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations, discuss the clinical importance of similarities and differences between a biosimilar insulin and a reference insulin, and describe key, clinically relevant data derived from pivotal trials of new and emerging insulin products. Dr. Beaser is Associate Professor of Medicine at Harvard Medical School and Senior Physician & Medical Director of CME at Joslin Diabetes Center. Dr. Segal is Professor of Pharmacy Practice at Massachusetts College of Pharmacy and Health Sciences (MCPHS) University and Clinical Pharmacist and Diabetes Educator at Joslin Diabetes Center.

Participants will be able to submit questions for the panel prior to and during the live broadcast, to be addressed in real time by the speakers. To submit a question prior to the program, please click here.

“The significant advances in the insulin replacement therapies that are now becoming available empower clinicians caring for people with diabetes to better replicate natural insulin action patterns, but in so doing, challenge those clinicians to learn to take full advantage of these new tools,” shared Dr. Richard Beaser. “Clinicians would therefore benefit from practical, expert-led education in order to understand the full spectrum of insulin replacement therapies which will insure that all of their patients who need these treatment options can have them available in a timely and effective manner. I’m thrilled to help present this series of programs on DiabetesSeriesLive to help arm them to do that.”

The following three additional programs will follow this autumn on http://www.DiabetesSeriesLive.com, expanding on new breakthroughs in insulin therapies:

Advancing to Insulin Therapy for Type 2 Diabetes: The Impact of the New Insulin Options will air live Thursday October, 29, 2017 1:00-2:00pm ET. Topics discussed will include recognizing the indications for advancement to insulin replacement therapy for people with Type 2 Diabetes and applying the important pharmacokinetic and pharmacodynamic properties of the new insulins and insulin combinations to clinical care. Dr Richard Beaser will be joined by Dr. Richard E. Pratley, the Samuel E. Crockett Chair in Diabetes Research; Director at Florida Hospital Diabetes Institute and Adjunct Professor at Sanford Burnham Presbys Medical Discovery Institute.

Physiologic Insulin Replacement: Practical Approaches for the Primary Care Provider will air live Thursday, November 30, 2017 12-1pm. Dr. Richard Beaser will be joined by Dr. Anne L. Peters and Dr. Jeremy H Pettus. Dr. Peters is Director, Clinical Diabetes Program and Professor, Keck School of Medicine at University of Southern California. Dr. Pettus is Assistant Professor of Medicine, Division of Endocrinology at University of California, San Diego.

Dr. Beaser, Dr. Peters and Dr. Pettus will remain for a second program at 1pm ET, titled The Evolution of Glycemic Monitoring and Insulin Delivery Devices: Why the Primary Care Provider Should Understand the Options. This will air live Thursday, November 30, 2017 1-2pm.

The first of these two programs will explore methods to utilize currently available insulins to more accurately replicate natural insulin secretory patterns. In the second program, the use of new devices will be discussed, including insulin pumps and glucose monitoring devices. Practical information will be provided for non-specialist clinicians to help them avail their patients of these tools when indicated.

Each program will be available online on http://www.DiabetesSeriesLive.com for 6 months after its live date for 1.0 AMA PRA Category 1 Credit(s)™, totaling 4.0 CME/ CE credits available for this series. Clinicians can register for the series on DiabetesSeriesLive.

This series is presented by Joslin Diabetes Center in joint providership with PlatformQ Health Education and are supported by educational grants from Novo Nordisk Inc. and Medtronic, Inc.

About PlatformQ Health

PlatformQ Health is the leading provider of live, online medical education events, operating 16 therapeutically aligned learning channels dedicated to providing clinicians, patients, caregivers, advocates and administrators rigorous, outcomes-centric education aimed at improving patient care. The company’s unique education platform allows physicians and other healthcare professionals to connect online from anywhere, to learn about the latest treatments options, and engage in real-time discussion with scientific, research and patient care experts.

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S. For more information, visit http://www.joslin.org or follow @joslindiabetes.

Boston, MA (PRWEB) August 09, 2017 – PlatformQ Health, in collaboration with the Bladder Cancer Advocacy Network (BCAN) and faculty from Mount Sinai School of Medicine and the UNC Lineberger Comprehensive Cancer Center, will present a series of live-online and enduring programs in bladder cancer to help educate and facilitate collaboration between doctors, patients and their larger care teams, with sessions dedicated to HCPs and patients, respectively. Both live, interactive programs will be made available on demand following the initial broadcast.

“This pair of programs addresses the specific educational needs of clinicians and patients. It is designed to support The American Society of Clinical Oncology’s reminder of the importance of a multidisciplinary, team-based clinical approach to care that emphasizes patients taking an active and informed role in treatment decisions,” shared Robert Rosenbloom, CEO PlatformQ Health. “With over 79,000 new cases of bladder cancer expected in the US in 2017, aligning clinician and patient understanding is critical to achieve the best possible outcome for every patient.”

Shared Education to Support Shared Decision-Making

The first session of the program, designed for healthcare professionals treating patients with bladder cancer, will air live online on OMedLive, PlatformQ Health’s oncology learning channel, August 11, 2017 from 11:00-12:00pm ET, with information about the new horizons in personalized care for metastatic bladder cancer. This one-hour accredited program, Bladder Cancer: Integrating Multidisciplinary Care into Practice, will award up to 1.0 AMA PRA Category 1 Credits™ and will cover:

  • • The latest clinical data of new and emerging agents
  • • Immunotherapy
  • • Chemotherapy selections
  • • Multimodal therapies
  • • Clinical trials for bladder cancer
  • • Multidisciplinary care

Clinicians can register for this free online CME here.

The second session, designed for patients and caregivers, Bladder Cancer: Be Active in Your Treatment and Self-Care, will air live online on CancerCoachLive, PlatformQ Health’s learning channel dedicated to cancer patient education, Friday, September 29, 2017 from 11:00am – 12:00pm ET. In this program, a panel of experts will help patients and caregivers understand their disease, what tests to expect, what’s involved in treating bladder cancer, and include a Q&A and guidance on how to take a more active role in their cancer care team. Patients and caregivers can register here.

“This pair of programs addresses the specific educational needs of clinicians and patients. It is designed to support The American Society of Clinical Oncology’s reminder of the importance of a multidisciplinary, team-based clinical approach to care that emphasizes patients taking an active and informed role in treatment decisions,” shared Robert Rosenbloom, CEO PlatformQ Health. “With over 79,000 new cases of bladder cancer expected in the US in 2017, aligning clinician and patient understanding is critical to achieve the best possible outcome for every patient.”

Speaker Line-up Announced, Experts from Mt. Sinai and Chapel Hill

Speakers for these programs come from Mount Sinai School of Medicine, UNC Lineberger Comprehensive Cancer Center, and the Bladder Cancer Advocacy Network (BCAN). The HCP session, Integrating Multidisciplinary Care into Practice, will be led by Matthew D. Galsky, MD and Matthew I. Milowsky, MD. Dr. Galsky is Professor of Medicine and Director, Genitourinary Medical Oncology at Mount Sinai School of Medicine. Dr. Milowsky is Associate Professor of Medicine, Section Chief, Genitourinary Oncology and Co-Director, Urologic Oncology Program at UNC Lineberger Comprehensive Cancer Center.

Dr. Galsky will be joined by two additional panelists for the patient session – doctors Mohamed and Chisolm, for Bladder Cancer: Be Active in your Treatment and Self-Care. Nihai Mohamed, PhD is Assistant Professor, Urology at Mount Sinai School of Medicine. Stephanie Chisolm, PhD is Director of Education and Research at the Bladder Cancer Advocacy Network (BCAN).

“BCAN strives to help patients ‘own your health’,” stated Stephanie Chisolm, Director of Education and Research at the Bladder Cancer Advocacy Network. “Trustworthy and engaging education is a critical component when moving patients from those receiving care to active participants in their journey. We are thrilled to be able to partner with PlatformQ Health on this initiative and offer this information to our members.”

Pre-Session Engagement to Sharpen Focus of Discussions

In addition to the live Q&A sessions, both panels will address pre-submitted questions on the programs’ respective question boards. Clinicians can submit questions and vote on their colleagues’ on OMedLive’s “QBoard” while patient/caregivers can visit CancerCoachLive’s “QBoard.”

This activity is supported by an independent educational grant from Genentech, Inc

About PlatformQ Health

PlatformQ Health is the leading provider of live, online medical education events, operating 16 therapeutically aligned learning channels dedicated to providing clinicians, patients, caregivers, advocates and administrators rigorous, outcomes-centric education aimed at improving patient care. The company’s unique education platform allows physicians and other healthcare professionals to connect online from anywhere, to learn about the latest treatments options, and engage in real-time discussion with scientific, research and patient care experts.

About Bladder Cancer Advocacy Network (BCAN)

BCAN was founded in 2005 and is the only national advocacy organization devoted to advancing bladder cancer research and supporting those impacted by the disease. BCAN is on the front-lines advocating for greater public awareness and increased funding for research to identify effective treatments and eventually, a cure for bladder cancer.

Boston, MA (PRWEB) July 20, 2017 – Acute myeloid leukemia (AML) is a rare and aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem cell transplant is often recommended to reduce the chance of reoccurrence and relapse. With such a challenging diagnosis that requires immediate action, patients and caregivers need accessible and trustworthy education in order to partner with their healthcare team and empower confidence throughout their treatment.

“We’re honored to once again be collaborating with The Leukemia & Lymphoma Society and CancerCoachLive to bring AML patients and caregivers the education they need at a critical time in their journey,” says PlatformQ Health’s CEO, Robert Rosenbloom. “As treatment is needed immediately after an AML diagnosis, many patients and caregivers will be joining in the midst of their battle, from hospital beds or from home. Our interactive online program makes it possible for them to ask questions and learn from top leukemia doctors, nurses and advocacy group leaders in an easily accessible format.”

Patients, caregivers and others interested in attending this free online program can learn more on CancerCoachLive.

This program comes on the heels of a highly successful inaugural virtual patient education program that LLS and PlatformQ Health held for patients with B-cell non-Hodgkin lymphoma (NHL) in 2016. “LLS is thrilled to work with PlatformQ Health again to educate another segment of the cancer patients we serve,” said Karen DeMairo, LLS Executive Director-Education & Integration. “Our first collaboration successfully educated over 600 patients and caregivers facing B-cell non-Hodgkin lymphoma with a level of in-depth education that makes a real difference in their lives. We are excited to now bring the same level of support to our AML community.”

Register for the program here.

This free patient education program, will help patients and caregivers answer some of the most oft-asked questions:

  • • What is acute myelogenous leukemia (AML)?
  • • How do test results help me and my doctors?
  • • What are my options for treatment?
  • • Where do I go for self-care information and support?

In addition to these questions, the presenters will be responding to participant questions taken before and during the live broadcast. Questions can be submitted prior to the program on CancerCoachLive’s Question (“Q”) Board.

The panelist for this hour-long program include Dr. David P. Steensma, Michelle Rajotte and Katherine Edmonds. David P. Steensma, MD, FACP is an Associate Professor of Medicine at Harvard Medical School and faculty member in the Division of Hematological Malignancies at Dana-Farber Cancer Institute. Dr. Steensma has more than 300 publications in peer-reviewed journals that include the New England Journal of Medicine, Blood, and Leukemia.

Michelle Rajotte, LMSW, is currently the Associate Director of The Leukemia & Lymphoma Society’s Information Resource Center (IRC) and has worked for The Leukemia & Lymphoma Society (LLS) for almost 12 years. As part of her role as Associate Director, she assists and educates those touched by blood cancers when they reach out to LLS for resources, information and support. Michelle has a Masters in Social Work from NYU and a Bachelor of Arts in Psychology from Quinnipiac University. In addition to working with blood cancer patients and their families, she also has experience assisting individuals with developmental disabilities, adults with psychiatric diagnoses, children and adolescents with various medical issues and children in foster care.

Katherine Edmonds, ARNP is a nurse practitioner in the leukemia program at the Dana-Farber Cancer Institute, and previously worked as a registered nurse in the Hematologic Malignancy Department while she completed her master’s degree at the MGH Institute of Health Professions. Katherine graduated from the NYU nursing school in 2006.

Support for this patient education program was provided by Pfizer Inc.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

About PlatformQ Health

PlatformQ Health is the leading provider of live, online medical education events, operating 16 therapeutically aligned learning channels dedicated to providing clinicians, patients, caregivers, advocates and administrators rigorous, outcomes-centric education aimed at improving patient care. The company’s unique education platform allows physicians and other healthcare professionals to connect online from anywhere, to learn about the latest treatments options, and engage in real-time discussion with scientific, research and patient care experts.

Boston, MA (PRWEB) June 19, 2017 – The National Stroke Association and NeuroCareLive, the recently launched patient education channel from the PlatformQ Health education network, have partnered to host the site’s inaugural live-online program on June 20, 2017 from 2:00-3:00PM ET. Titled, “Living with the Burden of PBA: Education for Patients and Caregivers” this immersive, expert-led program will be available for patients and caregivers at no cost and will include live video lectures with slides, interactive Q&A, and audience polling throughout. Participants are encouraged to bring their questions to submit during the live broadcast or share in the session’s “Qboard” ahead of time.

More than 7 million patients in the United States suffer from Pseudobulbar affect (PBA), a secondary, underlining condition that occurs in a variety of neurological brain diseases, including Alzheimer disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson disease, and patients who have suffered a stroke or brain injury. Characterized by frequent, unprovoked, and often uncontrollable episodes of laughing or crying, this involuntary and unpredictable condition is often mistakenly attributed to depression or other psychiatric disorders, when in fact it is a neurological condition.

Understanding the urgent need for patient education around conditions like PBA and many other neurological diseases, PlatformQ Health has launched its newest patient education platform NeuroCareLive, aimed at empowering patients and caregivers by providing them with the latest information and care options surrounding their condition.

“Often misunderstood, and as a result underreported and misdiagnosed, PBA impacts a patient’s quality of life, can result in social isolation, and often limits the patient’s work productivity. We are thrilled to collaborate with the National Stroke Association to help deliver meaningful education and resources to patients suffering from PBA and their caregivers,” shared PlatformQ Health CEO, Robert Rosenbloom. “This is the first of what will be a series of educational programs for patients with neurological diseases, like stroke, giving them an opportunity to engage with the faculty in a flexible, user-friendly format, within an individualized and self-paced learning environment that can accommodate the different needs of patients in the privacy and comfort of their own home.”

The presenters for this program come from the Cleveland Clinic. Erik P. Pioro, MD, PhD is a Neurologist specializing in the care of patients with ALS and other complex neurodegenerative motor neuron disorders. Dr. Pioro is the Director of the Section of ALS and Related Disorders at Cleveland Clinic, member of multiple professional associations, and author of numerous journal articles, book chapters and abstracts in the field. Maileen Ulep-Reed, MSN, APRN, FNP-BC is a nationally board-certified family nurse practitioner (NP) with the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada, and is currently a PhD candidate. In addition to working with patients needing neurologic care, Ms Ulep-Reed has served as a clinical instructor at the UNLV School of Nursing, co-chair and committee member for continuing education conferences for NPs, and is an active member of the American Association of Nurse Practitioners.

As a patient advocacy group, the National Stroke Association recognizes the need to innovate in the patient education space. “Our goal is to empower patients and ensure that they are aware of the most-up-to date information on their conditions,” according to Anna Taylor, Director of Programs at the National Stroke Association. “We are excited to partner with PlatformQ Health and bring this live and interactive educational program to our constituents.”

The origins of this patient-oriented program stem from findings from a recent CME-accredited program run in a sister learning channel in the PlatformQ Health network for HCP medical education in neurology, NeuroSeriesLive, from which a post-engagement survey found that 62% of clinician attendees reported their participation in the program had a positive impact on their patients and 78% had a positive impact on their clinical practice. It is anticipated that this one hour live program will make similar progress in helping patients with PBA and their caregivers to reduce their uncertainty and anxiety surrounding the condition and get the right treatment and support. The program aims to provide a greater understanding of the signs and symptoms of PBA and how it differs from psychiatric disorders, medical management can help, and strategies for self-care that minimize the burden of PBA and improve quality of life.

About the National Stroke Association

The National Stroke Association was founded in 1984 as the only national association devoted 100% to support stroke rehabilitation and prevention efforts. The National Stroke Association offers free education, resources, services, and legislative advocacy focused on the needs of stroke survivors, caregivers and healthcare professionals in the stroke community nationwide. They actively provide services to about 90,000 stroke survivors, 30,000 caregivers, and more than 110,000 healthcare professionals in the U.S. and Canada; and the number is growing every day.

About PlatformQ Health

PlatformQ Health is the leading provider of live, online medical education events, operating 16 therapeutically aligned learning channels dedicated to providing clinicians, patients, caregivers, advocates and administrators rigorous, outcome-centric education aimed at improving patient care. The company’s unique education platform allows physicians and other healthcare professionals to connect online from anywhere, to learn about the latest treatments options, and engage in real-time discussion with scientific, research and patient care experts.

Boston, MA (PRWEB) June 14, 2017 – PlatformQ Health, the leading provider of live-online medical education events announces its collaboration with LUGPA (Large Urology Group Practice Association), a medical trade association that represents more than 2,300 U.S. urologists, administrators and their independent urology group practices, to kick off the launch of UroCareLive, an online learning platform that includes features of a live medical conference, via a monthly Virtual Crossfire Event Series.

UroCareLive offers live streaming video lectures, panel discussions and case presentations, as well as interactive activities such as real-time question and answer sessions with top faculty and other participants. The newest medical learning channel from the PlatformQ Health network, UroCareLive represents PlatformQ Health’s continuing mission to deliver the most timely, relevant, reliable education to HCPs and patient audiences in partnership with leading institutions and therapeutically aligned organizations.

“We are thrilled to further expand PlatformQ Health’s online educational offerings to include a channel that will allow urologists and others involved in urology care an opportunity to connect online with world-renowned medical experts in a live, interactive setting,” says CEO Robert Rosenbloom. “Our collaboration with LUGPA makes UroCareLive’s introduction even more meaningful, as many of the nation’s urology practices prepare to participate in the inaugural series focused on addressing the clinical and business topics that are most important to urologists today.”

UroCareLive’s first program, Developing an Effective Advanced Prostate Cancer Clinic, will air live online June 27, 2017 at 12:00 PM EST, featuring:

  • • Dr. Neal D. Shore, MD, FACS, President, LUGPA (Large Urology Group Practice Association)
  • • Earl L. Walz, CEO, The Urology Group
  • • Bob Asinof, CEO, Urology Center of Colorado
  • • Dr. Paul R. Sieber, MD, President and Medical Director of Research, Lancaster Urology
  • • Dr. Bryan A. Mehlhaff, MD, Oregon Urology Institute

Participants are able to submit questions for the expert panel prior to and during the live broadcast, allowing presenters to respond in real time, combining benefits of in-person interactive education with the convenience of digital access.

The first of a regular Virtual Crossfire Event Series, the program will kick off a year’s worth of interactive online events for LUGPA members and the greater urology community. Select programs will be eligible for CME credit. Other programs in development include…

  • • Immunotherapy for Bladder Cancer
  • • Developing an Effective Advanced Bladder Cancer Clinic
  • • Health Policy: Update & Impact of Healthcare Reform and Policy
  • • Navigating the Financial Aspects of Practice Management
  • • The Future of Urology Practices: Independent, Hospital-Owned or Private
  • • Peyronies, Implants & Sphincter Therapies

The enduring, virtual education series will be available free of charge and is recommended to any physician, administrator, or other healthcare provider interested in developing or the business of an effective advanced prostate cancer clinic. LUGPA members will have the added benefit of watching and participating in the live online broadcast June 27 at 12PM EST.

“LUGPA continuously strives to deliver practical and real-world value to our independent urology practice members through convenient, frequent and novel educational initiatives. We are very pleased to now offer information dissemination through live, interactive online programs via UroCareLive,” said Neal D. Shore, MD, LUGPA President.

Participants can pre-register for this and future live and enduring events at UroCareLive, while questions for the initial program’s panel can be submitted here. For more information about UroCareLive and LUGPA’s 2017 monthly Virtual Crossfire Event Series, visit our UroCareLive.com or lugpa.org.

About LUGPA

LUGPA currently represents more than 25 percent of the nation’s urology practices, comprising more than 2,300 members, who account for approximately 30 percent of urologic care in the United States. The Association is committed to providing the best resources to its member practices through advocacy, research, data collection and benchmarking efforts. LUGPA advocates for independent urology practices by promoting quality clinical outcomes, fostering new opportunities and improving advocacy in legislative and regulatory arenas.

About PlatformQ Health

PlatformQ Health is the leading provider of live, online medical education events, operating 16 therapeutically aligned learning channels dedicated to providing clinicians, patients, caregivers, advocates and administrators rigorous, outcome-centric education aimed at improving patient care. The company’s unique education platform allows physicians and other healthcare professionals to connect online from anywhere, to learn about the latest treatments options, and engage in real-time discussion with scientific, research and patient care experts.

Boston, MA (PRWEB) March 22, 2017 – High cholesterol — particularly a high level of low-density lipoprotein cholesterol (LDL-C) — is a main risk factor for developing cardiovascular disease (CVD), the number one cause of death in the United States. Treatment with statins has been shown to effectively lower LDL-C, but not for everyone. About 70% of patients with elevated LDL-C levels go untreated due to statin resistance, statin intolerance, familial hypercholesterolemia not well controlled on statins and nonadherence to statin treatment. For these patients, a newer class of injectable drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, represents one of the most promising strategies.

To help educate clinicians on PCSK9 inhibitors and CVD risk reduction, the National Lipid Association and PlatformQ Health are partnering to produce a two-part online series airing on CardioCareLive.com.

Part 1 – The Emerging Role of PCSK9 Inhibitors and CV Risk Reduction

Live: Tuesday, April 11, 2017 2:00 PM – 3:00 PM ET

Part 2 – CVD and PCSK9 Inhibitors: Analyzing the Outcome Studies and Understanding Their Implications

Live: Tuesday, May 23, 2017 11:00 AM – 12:00 PM ET

CME credit provided by the National Lipid Association.

These activities have been approved for AMA PRA CATEGORY 1 CREDIT™.

These activities are eligible for ACPE and ANCC credit.

Clinicians can Register Here for the Series

Speakers:

  • • Michael J. Blaha, MD, MPH; Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine, Johns Hopkins University
  • • Michael Miller, MD, FACC, FAHA; Professor of Cardiovascular Medicine, Epidemiology & Public Health; University of Maryland School of Medicine
  • • Marc S. Sabatine, MD, MPH; Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine, Brigham and Women’s Hospital; Professor, Harvard Medical School

Featuring a panel of experts live-streamed through PlatformQ Health’s virtual learning channel CardioCareLive.com, each session includes an in-depth slide presentation, real-time Q&A and interactive polling. “PlatformQ Health always aims to partner with trusted organizations like the National Lipid Association to ensure our programs have the most positive impact possible,” says Robert Rosenbloom, CEO of PlatformQ Health. “We are especially honored to work with NLA to support clinicians treating such a deadly and far-reaching condition as cardiovascular disease.”

The series provides an accessible and timely means for clinicians to stay abreast of changing treatment options as well as the recommendations of the most current guidelines on their optimal use. “The lipid-lowering field is evolving at an ever-accelerating rate,” says speaker Michael J. Blaha, MD. “With new studies at nearly every major meeting, clinicians need succinct summaries of the latest evidence and how to apply it in their practice.” Improved knowledge of the updated guidelines and the benefits and risks of newer therapies will provide clinicians with the tools to select the optimal LDL-C-lowering regimens, address concerns, and improve adherence, to more effectively lower cardiovascular risk in their patients.

Topics of Interest

  • • Treatment options beyond statins to decrease lipid-related CV risk in patients with hypercholesterolemia
  • • Newer therapeutic options for patients with familial hypercholesterolemia
  • • Pharmacological action of PCSK9 inhibitors and their role in decreasing risk of cardiovascular disease
  • • Recent efficacy and safety clinical trial data from PCSK9 inhibitor cardiovascular outcomes trials

About PlatformQ Health

PlatformQ Health is the leading provider of live online medical education events, with 15 websites dedicated to different therapeutic areas. Their unique education platform allows physicians and other healthcare professionals to connect online from any computer, learn about the latest treatments options, and engage in real-time Q&A with top faculty.

About National Lipid Association

The NLA is a 501c(6) non-profit medical association that focuses on providing education, training, and resources on lipid management and the prevention of CVD to healthcare professionals. The NLA has been granted Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME). The NLA is also a jointly accredited provider by the Accreditation Council for Pharmacy Education (ACPE), American Nurses Credentialing Center (ANCC), and the Commission on Dietetic Registration (CDR). NLA CME/CE activities have engaged nearly 50,000 participants and readers who have earned more than 15,000 CME/CE certificates to date.

Boston, MA (PRWEB) February 24, 2017 – Age-related macular degeneration (AMD) is a chronic disease and the leading cause of irreversible blindness in the elderly of industrialized countries. The advanced form of dry AMD is geographic atrophy (GA) or atrophic AMD, a progressive, irreversible and blinding disease for which effective treatment remains a significant unmet medical need.

Optometrists play a crucial role in the ongoing eye care of patients with AMD and GA, from screening to combining imaging or functional data with a careful patient history to determining the need for subsequent care. They readily assess recognized risk factors with advanced AMD and provide disease management in the early stages, as well as prompt referral and follow up after treatment.

However, as a practical consideration for delivering eye care, the historic methodology of optometric practice may not keep pace with population aging, which leads to a corresponding increase in the prevalence of several macular diseases, and there are proportionally fewer eye care providers to care for older patients.

To help close this gap, the New England College of Optometry (NECO) and PlatformQ Health are partnering to launch a free online CE series on ClinicalSeriesLive, one of PlatformQ Health’s virtual learning channels. “PlatformQ Health is honored to partner with NECO on this innovative series for optometry health care professionals,” says Robert Rosenbloom, CEO of PlatformQ Health. “We look forward to helping bring much needed attention to the most prevalent cause of blindness in our aging population.”

Clinicians can engage live with two top optometry faculty:

1. Rishi P. Singh, MD, Associate Professor of Ophthalmology at Lerner College of Medicine, Staff Surgeon at Cole Eye Institute, and Medical Director of Informatics at Cleveland Clinic;

2. Mark T. Dunbar, OD, FAAO, Director of Optometric Services and Optometry Residency Supervisor at Bascom Palmer Eye Institute, University of Miami Health System.

“Age related macular degeneration is the leading cause of visual loss in older adults. Thus far, diagnosis and treatment have been limited to the wet or exudative form of this disease. New emerging insights in the dry or non-exudative form have added a significant understanding to the mechanisms of this disease,” says Rishi P. Singh, MD. “This online series will educate those on the front line — optometrist, ophthalmologist, and retina specialists — on screening, diagnosis, as well as future treatments which might be available.”

This program intends to improve awareness, knowledge, and competency of optometrists about AMD and GA. The three-part series will cover screening, how to interpret results, underlying pathophysiology, the importance of referral to specialists, the crucial role of follow up, monitoring of therapeutic response in patients receiving treatment, and more. All three programs will be available on-demand following the live broadcasts.

Details on the series:

New Insights into Age-Related Macular Degeneration and Geographic Atrophy

Session I – Geographic Atrophy: Causes and Consequences

Thursday, May 18, 2017 from 3:00-4:00 PM ET

Session II – The Referral to the Ophthalmologist and Treatment Options for Patients with Geographic Atrophy

Thursday, May 18, 2017 from 4:00-5:00 PM ET

Session III – Focus on the Patient: Empowering Communication for Improved Outcomes

Wednesday, July 12, 2017 from 2:00-3:00 PM ET.

Tpoics of Interest:

  • • Pathogenesis and natural history of the AMD and progression to GA
  • • Monitoring parameters for AMD and GA, and considering clinical and imaging findings
  • • Points of referral to a retinologist for AMD progression and treatment
  • • Patient education and management with multiple and often coexisting disorders
  • • Role in post-treatment management of the patient

Register Here

About New England College of Optometry

New England College of Optometry, NECO, is an independent graduate college of optometry that educates students for careers in eye care delivery, research, and education. For over 120 years, New England College of Optometry has been educating optometrists and leaders in the field. Originally founded in 1894 as the Klein School of Optics, NECO prepares the next generation of eye care providers, educators, leaders, and innovators through a rigorous curriculum and extensive clinical experiences. http://www.neco.edu

About PlatformQ Health

PlatformQ Health is the leading provider of live online medical education events, with 15 websites dedicated to different therapeutic areas. Their unique education platform allows physicians and other healthcare professionals to connect online from any computer, learn about the latest treatments options, and engage in real-time Q&A with top faculty. http://www.platformqhealth.com

Boston, MA (PRWEB) February 23, 2017 – Not everyone with neuroendocrine tumors (NETs) develops carcinoid syndrome, which typically involves intense diarrhea and facial flushing but can progress to breathing and heart problems if left untreated. For patients who do, understanding the symptoms and staying aware of current and emerging treatments is essential. However, healthcare providers often lack the time and resources to adequately educate every patient during office visits.

To help bring a higher quality of life to patients suffering from carcinoid syndrome, PlatformQ Health is partnering with the Carcinoid Cancer Foundation (CCF) on a free online program to air on CancerCoachLive, PlatformQ Health’s education platform for cancer patients.

Patient Education on Carcinoid Syndrome from Diagnosis to Treatment

Wednesday, March 1, 2017

11:00AM to 12:00PM EST

Led by Edward Wolin, MD, internationally renowned neuroendocrine cancer specialist and Director of the Neuroendocrine Tumor Program at Montefiore Einstein Center for Cancer Care, the program with feature a panel of speakers including Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, and three patients who will share their experience and answer questions from the audience.

“We hope this program will both educate and empower neuroendocrine tumor patients about carcinoid syndrome, helping them to live the best quality of life possible with this rare disease,” says Grace Goldstein. “We also want to educate healthcare professionals who may not see many carcinoid syndrome patients as well as members of the public who may be seeking a diagnosis.”

A live video stream of the panel will accompany an interactive slide show of clinically vetted content designed to reach a diverse group of patients. The program with also be live-streamed on Facebook and available on demand after the live session.

Direct patient education is not new for PlatformQ Health, given its award-winning programs in Diabetic Retinopathy and recent program focused on non-Hodgkin lymphomas. However, its history is rooted in leading data-centric, high engagement online Continuing Education for clinicians.

“We have seen enormous benefit to our clinician community who need easy access to the highest quality Continuing Education,” says Robert Rosenbloom, CEO and Founder of PlatformQ Health. “Through bringing the same standard of education while partnering with a trusted advocacy organization like Carcinoid Cancer Foundation, CancerCoachLive is helping meet the critical need cancer patients have for trustworthy education.”

With CancerCoachLive, organizations that serve cancer patients everywhere will be able to invite their members to participate in immersive, interactive online educational events that help empower them as they embark on their treatment journey.

Are you a patient or caregiver facing carcinoid syndrome? Join this expert panel on March 1, 2017 at 11AM EST by registering here.

*Support for this patient education program was provided by Lexicon Pharmaceuticals, Inc.

Boston – January 24, 2017 – LUGPA, a medical trade association that represents independent urology group practices including more than 2,200 US Urologists, today announced its collaboration with PlatformQ Health to develop a virtual education series. The monthly Virtual Crossfire Event Series aims to advance education for its community of independent urology practices. Throughout 2017, LUGPA members can experience in-depth discussions on topics ranging from the business impact of telemedicine and the CHIP Reauthorization Act to preparing practices for MACRA as well as controversial topics for both business and clinical integration. Select programs will be eligible for CME credits.

“LUGPA looks forward to collaborating with PlatformQ Health in order to provide our members up-to-date virtual education on issues that are critical to independent urology practices, “says LUGPA President Neal D. Shore, MD, FACS. “LUGPA is dedicated to providing novel educational initiatives for our member urology practices for their present and future success. We are pleased to introduce the cutting-edge Virtual Crossfire Event Series, as another benefit of LUGPA membership.”

Each 30 to 60-minute program will feature a live-streamed panel of experts on PlatformQ Health’s clinicalserieslive.com. The series will also be available on demand and on LUGPA member’s website. PlatformQ Health’s virtual education platform allows presenters to respond to real-time questions and audience polling, combining the benefits of in-person interactive education with the convenience of digital access.

“PlatformQ Health is honored to be partnering with an association so committed to educating its members. LUGPA has consistently brought forward both the best educators and the most relevant areas of study,” says CEO Robert Rosenbloom. “We are excited to be supporting the educational needs of the urology community.”

Find out more and register for LUGPA’s 2017 monthly Virtual Crossfire Event Series here.

About LUGPA

LUGPA currently represents more than 25 percent of the nation’s urology practices, comprising more than 2,200 members, who account for approximately 30 percent of urologic care in the United States. The Association is committed to providing the best resources to its member practices through advocacy, research, data collection and benchmarking efforts

About PlatformQ Health

PlatformQ Health is the leading provider of live online medical education events, with 15 websites dedicated to different therapeutic areas. Their unique education platform allows physicians and other healthcare professionals to connect online from any computer, learn about the latest treatments options, and engage in real-time Q&A with top faculty.

Boston – November 8, 2016 – Obesity poses one of the biggest public health challenges we face today, resulting in a large disease burden of multiple chronic conditions, and imposing substantial cost to individuals, the healthcare system and society at large. With one-third of the adult US population overweight or obese, health care providers must be prepared to confront this complex disease and identify the optimal management approach for each individual patient.

To help spread the knowledge, PlatformQ Health is launching a new website, ObesitySeriesLive, that will provide live, interactive medical education activities for clinicians treating obesity. Both Boston University and The Obesity Society are joining as partners for the inaugural program.

“Obesity is one of the most personal and emotionally laden health challenges facing a staggering number of children and adults today. Not only does it impact essentially every organ system of the body, obesity has causes and consequences across a complex social, physiological and economic landscape. As clinicians see an increasing percentage of patients with obesity, comprehensive continuing medical education becomes essential to address both individual patient care and the larger epidemic,” says Caroline Apovian, MD, Vice President of The Obesity Society and Professor of Medicine and Pediatrics at Boston University School of Medicine.

“Partnering with The Obesity Society and Boston University for the inaugural program of ObesitySeriesLive is the best kind of collaboration we could have hoped for,” says Robert Rosenbloom, CEO and Founder of PlatformQ Health. “Together we bring the full picture: medical expertise, deep patient understanding, and excellence in online education. It’s sure to be a great first program.”

Primary care physicians, gastroenterologists, surgeons, pharmacists, nurses, nurse practitioners and other clinicians involved in the treatment and management of obesity are encouraged to join.

Expert Management Perspectives and Updates from Obesity Week

Friday, November 11th from 12:00 – 1:00PM ET.

Speakers:

Caroline Apovian, MD of Boston University School of Medicine

W. Scott Butsch, MD of Massachusetts General Hospital

Learn More and Register Here

About PlatformQ Health

PlatformQ Health is the parent company of over twelve CME platforms dedicated to different therapeutic areas, from oncology to neurology. PlatformQ Health offers advanced, accredited and complementary medical education to clinicians in a highly accessible and convenient format, with live and on demand programs that include all of the features of an in-person medical conference such as lectures, panel discussions and case presentations as well as interactive polling and Q&A sessions with top faculty.

About The Obesity Society

The Obesity Society (TOS) is the leading professional society dedicated to better understanding, preventing and treating obesity. Through research, education and advocacy, TOS is committed to improving the lives of those affected by the disease.

Boston – November 2, 2016 – Lung cancer claims more lives in the U.S. than breast, prostate and colon cancer combined. To help raise awareness, November has been designated Lung Cancer Awareness Month, and OMedLive is joining the cause with three complementary continuing medical education programs for clinicians treating advanced lung cancers.

The statistics are tough. According to the American Lung Association, 158,080 people will likely die from lung cancer in 2016, many less than a year after receiving the harrowing news. For clinicians, the often short window of treatment time means that their own expertise marks a watershed in the life of each lung cancer patient. Thankfully, many recent medical advances are providing hope.

“We are making tremendous headway in the development of potent yet tolerable targeted therapies for advanced lung cancers,” says Geoffrey R. Oxnard, M.D., thoracic oncologist at Dana-Farber Cancer Institute and Assistant Professor at Harvard Medical School.

“To offer our patients the best care, we need to be familiar with the growing range of therapies which are emerging onto the market.”

Recent insight into molecular and genetic profiling of non-small cell lung cancer (NSCLC) tumors, which constitute up to 90% of lung cancers, as well as emerging immunotherapies have expanded and personalized treatment options.

To help spread the knowledge, OMedLive is offering the following three complimentary CME programs for medical oncologists, oncology nurses, nurse practitioners, physician assistants, primary care physicians, pulmonologists, and others interested in the therapeutic management of patients with lung cancer.

Immunotherapy: Shifting the Lung Cancer Treatment Paradigm: November 3rd, 2:00 – 3:00PM EST

Learn More and Register Here

Updates in the Lung Cancer: Targeting the Epidermal Growth Factor Receptor

Learn More and Register Here

Updates in Lung Cancer: ALK Inhibition in the Treatment of NSCLC

Learn More and Register Here

About OMedLive

OMedLive is an online CME learning platform from PlatformQ Health that offers advanced, accredited and complementary medical education to clinicians in a highly accessible and convenient format. OMedLive’s programs are available live and on demand, and include all of the features of an in-person medical conference such as lectures, panel discussions and case presentations as well as interactive polling and Q&A sessions with top faculty.

Boston – September 27, 2016 – Clinicians have diagnosed over 30 million people with heart failure in the United States. A syndrome characterized by high mortality, frequent hospitalization and reduced quality of life, heart failure is difficult to treat and about 50% of patients will die from it within five years of a diagnosis.

Improving clinicians’ understanding of heart failure pathophysiology, new medications, surgical interventions and mechanical devices is our best hope in the face of such stark statistics.

Beginning today, September 27th, CardioCareLive is hosting the Heart Failure Summit, a three-part complementary CME program for cardiologists, internal medicine and primary care physicians, nurses and other health care professionals that treat patients with heart failure.

Advances in Heart Failure Management: Improving Outcomes with Innovation

September 27, 2016: 1:00 – 3:00PM EST

November 1, 2016: 2:00 PM – 3:00 PM EST

Taught by cardiac specialists and professors from Harvard Medical School — Doctors James L. Januzzi, Akshay Suvas Desai and Jagmeet P. Singh— the program aims to provide practical guidance on recent advances in heart failure management to facilitate informed, individualized treatment decisions.

“Heart failure is an increasingly prevalent diagnosis, associated with high risk and spiraling healthcare costs. Clinicians will benefit from an understanding of optimal means to identify and treat this escalating problem,” says James L. Januzzi, MD, FACC, FESC and Professor of Medicine at Harvard Medical School.

Clinicians can learn more and register here. The entire heart failure program will also be available on demand after the live airing.

Aliso Viejo, California – September 14, 2016 – Global Genes and PlatformQ Health are pleased to announce that the sold-out 5th Annual RARE Patient Advocacy Summit™ taking place in Huntington Beach, CA September 22 – 23 will be streamed live online at RareUniversity.com, the new rare disease educational site created in partnership between Global Genes and PlatformQ Health. Mindful of the many rare disease community members who can’t attend the Summit in person, RareUniversity will stream four topically aligned breakout tracks each day totaling over 70 hours of programming for free.

Register Here for the live streams

This year’s two-day RARE Summit features leading minds from across the rare disease landscape. Members of the rare disease community unable to attend in person will have direct access to expert presentations live and on demand, from guidance on the drug development pipeline and translational research updates to advice on building an army of advocates and supporters. Each day, four public, live streams will be available:

  • Day 1: Care & Support
  • Day 1: What You Need To Build a Disease Community
  • Day 1: Patient’s Role in Drug Discovery, Pre-Clinical Tools
  • Day 1: Science & Technology Updates
  • Day 2: Capacity Building
  • Day 2: Patient Activism
  • Day 2: Patient’s Role in Drug Discovery, Research & Clinical Trials
  • Day 2: Science & Technology Updates

RareUniversity is an educational platform purpose-built to bring together key stakeholders currently driving progress in rare disease education, research and development. Intended for patients, patient advocates and clinicians, RareUniversity is committed to providing Tethered Education™, an approach that meets the diverse needs of each group while aligning medical information and clinical research education across the community. The live streamed RARE Summit is just the beginning of the programs RareUniversity will offer.

“RareUniversity is both a response to the needs of the rare disease community and another stake in the ground regarding the future of medical education. Patients, clinicians, membership organizations, researchers and even industry need to be resources for each other and collaborators for better medical outcomes. This platform will facilitate these collaborations and build solidarity for families and the medical community,” says Robert Rosenbloom, CEO at PlatformQ Health.

“This collaboration is critical in two ways; first, it provides an opportunity for Global Genes to create an inclusive experience for patient advocates anywhere to participate in our highly anticipated annual RARE Patient Advocacy Summit. Second, this will feed important content into what will ultimately become one of the most compelling sources for rare disease education,” says Nicole Boice, CEO Global Genes. “The Rare University is a brainchild produced by the brilliant minds of our Corporate Alliance, and we are very grateful for their contributions.”

To learn more about RareUniversity and educational program sponsorship opportunities, visit rareuniversity.com/contact-us/.

About Global Genes

Global Genes is a leading global advocacy non-profit organization for patients and families fighting rare and genetic diseases. Global Genes works to eliminate rare and genetic disease challenges by building awareness, developing patient-focused educational tools, and funding patient care programs and early investigative research. Recognized worldwide by the Blue Denim Genes Ribbon™, Global Genes is dedicated to uniting experts, advocates, patients and their families. The organization seeks to help find treatments and cures for the 7,000+ rare and genetic diseases that affect an estimated 30 million Americans and over 350 million people worldwide.

About RareUniversity and PlatformQ Health

PlatformQ Health is a leading online medical education event platform, with over a dozen therapeutically aligned websites. Holding over 100 CME/CE-accredited sessions a year, PlatformQ Health works in partnership with clinical and research centers of excellence and leading accrediting partners. RareUniversity and the parntership with Global Genes represents the next evolution of PlatformQ Health’s commitment to aligning the highest standard of medical education across the healthcare community including clinicians, patients, caretakers and patient advocates.

Boston – August 9, 2016 – Humanity has long relied on a mechanism in the kidneys that stores excess glucose to survive periodic famines. But, as industrialized nations began to overcome starvation, an over-abundance of cheap, sugary foods entered our diets. And that same survival mechanism has now become a health risk for millions who struggle with Type 2 diabetes.

According to the CDC, “86 million U.S. adults have prediabetes, where their blood sugar levels are higher than normal… 15 percent to 30 percent of people with prediabetes will develop type 2 diabetes within five years.” That equates to more than one in three U.S. adults facing an increased risk of serious health problems such as vision loss, heart disease, stroke, kidney failure, amputations and premature death.

However, a relatively new class of oral medications designed to inhibit the kidney’s mechanism that reabsorbs 90% of the body’s excess glucose intake — sodium-glucose cotransporter-2 (SGLT2) — is showing great promise.

To help improve clinicians’ understanding of SGLT2 inhibitors, Joslin Diabetes Center, an academic affiliate of Harvard Medical School, and DiabetesSeriesLive will host the inaugural session of their new Virtual Symposia Series with a one-hour CME program on SGLT2 inhibitors and their treatment outcomes. The series will continue through 2017 and cover a wide range of diabetes topics including a Fall program on Basal Insulins.

The SGLT2 session will be presented by Nuha El Sayed, MD, Director of International Training Programs at Joslin Diabetes Center along with Richard Beaser, MD of Harvard Medical School.

“Our evolving understanding of the etiology and natural history of type 2 diabetes has brought to light a complex array of contributing factors, thus expanding the number of potential pharmacotherapeutic targets. One such factor is the renal enzyme SGLT2, which is involved in glucose reabsorption. Inhibiting this enzyme can be an effective treatment for the hyperglycemia of type 2 diabetes,” says Richard Beaser, MD. “This important CME session will help clinicians identify the benefits and risks of SGLT2 inhibitors, and enhance their skills in using them, when indicated, to achieve therapeutic goals.”

In accreditation partnership with the Primary Care Network, the online CME session will take place August 10, 11 am – Noon EST at DiabetesSeriesLive.com, a medical education website from PlatformQ Health.

“DiabetesSeriesLive offers an effective way for clinicians who see people suffering from diabetes every day to stay current on advances in care without leaving their office,” says Platform Q Health CEO Robert Rosenbloom. “After much discussion with our medical advisors, we feel that a thorough understanding of SGLT2 inhibitors is vital for effectively treating type 2 diabetes.”

There is no cost to register or watch any educational session on DiabetesSeriesLive. Live session attendance is encouraged, so clinicians can take advantage of interactive capabilities like submitting questions for live responses and interactive polling. The program will also be available on demand after the live event.

Endocrinologist, hospitalists, internists, primary care clinicians, nurses and others treating type 2 diabetes can register here.

Boston – July 28, 2016 – While so much effort goes into educating the public around cancer prevention, cancer remains largely unpredictable and many thousands each year will be diagnosed. When they are, one critical factor in treatment success is the time it takes to forming a patient’s response plan. As such, PlatformQ Health is launching a new education platform, CancerCoachLive, to empower newly diagnosed cancer patients.

In partnership with The Leukemia & Lymphoma Society, the inaugural CancerCoachLive program on August 4th will focus on Non-Hodgkin Lymphomas (NHL). About 70,00 people in the U.S. alone are diagnosed with NHL every year. And each of them needs to understand their subtype — which NHL has about 60 of — in order to determine the type of treatment they are facing. Of the two major subtypes, B-cell lymphoma represents roughly 85%. Educating B-cell lymphoma patients and their caregivers can not only improve treatment outcome, but help them to face such a life-changing circumstance with confidence.

Presented by leading medical faculty from the University of Nebraska and Dana-Farber Cancer Institute, the program will allow lymphoma patients and their caregivers to discuss and share their questions, experiences and get advice via CancerCoachLive’s virtual learning channel. It will also be available on demand after the live session.

Direct patient education is not new for PlatformQ Health, given its award-winning programs in Diabetic Retinopathy. However, its history is rooted in leading data-centric, high engagement online Continuing Medical Education sessions for clinicians. Robert Rosenbloom, CEO and Founder of PlatformQ Health, says, “We have seen enormous benefit to our clinician community who need easy access to the highest quality Continuing Medical Education. We are excited to bring the same rigorous standard of education to our patient programs at CancerCoachLive.”

“Education is one of the best tools we can provide to our patients. By educating them about their disease and treatments, they are able to make better decisions throughout their cancer journey,” Karen Demairo, Executive Director- Education & integration, LLS.

Partnering with a long-trusted advocacy organization like LLS means CancerCoachLive is helping meet the critical need newly diagnosed patients have for trustworthy education. With CancerCoachLive, organizations that serve cancer patients everywhere will be able to invite their members to participate in immersive, interactive online educational events that help empower them as they embark on their treatment journey.

Are you a patient or caregiver facing B-cell non-Hodgkin lymphoma? Join this expert panel on August 4, 2016 at 2PM EDT by registering here.

This activity is supported by an educational grant from Pharmacyclics LLC, an Abbvie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and a grant from Genentech.

Boston – July 19, 2016 – Prostate cancer is the most common and fifth-leading cause of death from cancer in men. In 2014 alone, an estimated 233,000 cases were diagnosed. And, while almost 90% of cases are caught early with prostate-specific antigen (PSA) screening, up to 40% will still develop metastases and worsen despite advancing treatment options. Clinical challenges, such as optimal sequences of therapies and ideal combinations of therapies, can often hinder results.

To help save lives, PlatformQ Health is launching a new online education platform, VirtualProstateSummit.com, with complimentary CME-accredited programs for clinicians involved in the management of patients with prostate cancer. The new event platform kicks off with Evolving Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer, held on July 27th, 2016 from 10am to noon EST.

“The field of prostate cancer therapeutics is rapidly changing with the development of new hormonal therapies, radiopharmaceuticals, immune therapies, and novel chemotherapies for metastatic disease,” says Dr. Andrew Armstrong. “In addition, precision medicine approaches in biomarker defined populations are likely to change the practice of medicine in this disease in the near future. This two-part CME program will provide an update in the treatments of men with hormone-sensitive and castration-resistant prostate cancer, and discuss both standard and new investigational approaches to treating this disease.”

This inaugural program will be presented by faculty from Duke University including Director of Genitourinary Medical Oncology Daniel J. George, MD and Associate Professor of Medicine and Surgery Andrew J. Armstrong, MD. Medical oncologist, urologists and other healthcare professionals treating prostate cancer can register here.

“Online continuing education is being adopted in every field, but offers particular advantages to busy doctors that need the most up-to-date information,” said Robert Rosenbloom, Co-Founder and CEO of PlatformQ Health. “Prostate cancer impacts so many lives and we are thrilled to offer VirtualProstateSummit as a hub for exchanging knowledge to battle this prolific disease.”

At the conclusion of this activity, participants will be able to:

  • Address barriers to the optimal use of new therapies in patients with prostate cancer
  • Evaluate relative safety, efficacy, and tolerability on therapeutic options for prostate cancer and potential sequencing combinations for those patients with suboptimal responses
  • Address barriers to the optimal use of new therapies in patients with prostate cancer
  • Identify and assess relative safety, efficacy, and tolerability on therapeutic options for metastatic castration-resistant prostate cancer

Health care professionals can sign up for the event here.

The activity has been planned and implemented in accordance with requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Albert Einstein College of Medicine and Montefiore Medical Center and PlatformQ Health Education, LLC. The Albert Einstein College of Medicine and Montefiore Medical Center is accredited by the ACCME to provide continuing medical education for physicians.

Boston – April 21, 2016 – In the past decade, the MS treatment landscape has advanced dramatically and continues to rapidly evolve. An increasing number of disease-modifying therapies (DMTs) slow disease progression by preventing acute exacerbations and new lesion formation. This year’s annual meeting of the American Academy of Neurology (AAN), to be held in Vancouver, British Columbia, Canada, April 15-21, 2016, is the premier meeting for clinicians and researchers in neurology and a key meeting for those involved in MS care and research. The 2016 AAN meeting will attract nearly 14,000 attendees and will include nearly 700 abstracts in this area.

This seminal meeting is of the utmost importance to clinicians because of its coverage on MS diagnosis and disease evaluation, underlying pathophysiology, current and emerging therapies, and other management strategies. Expert commentary on key presentations from AAN will be presented live-online, affording clinicians a live Q&A with the experts immediately following the meeting.

Fred Lublin, MD, Saunders Family Professor of Neurology from the Mount Sinai Hospital, and Patricia K Coyle, MD, Professor and Acting Chair, Department of Neurology from Stony Brook University, will review the biggest stories in MS from the 2016 AAN conference in a one-hour online CME program hosted by NeuroSerieslive.com.

Attendees will receive MS updates from AAN to better be able to: evaluate recent clinical trial data and efficacy of current and emerging DMTs for MS; apply appropriate treatment selection their MS patients; and develop individualized, evidence-based treatment plans for MS patients based on the most up-to-date, expert-recommended therapy selection strategies – including when and how to advance MS therapy, and managing actively or aggressive progressing disease.

We recommend this CME program neurologists, neurology nurses, nurse practitioners and physician assistants, as well as primary care clinicians who manage patients with multiple sclerosis.

The complimentary, online CME session will take place Tuesday, April 26th, 2016 1:00 PM – 2:00 PM EST at NeuroSeriesLive.com. This activity is supported by educational grants from Genentech.

EO Robert Rosenbloom said, “Providing up-to-date, expert guidance on what’s new in MS can’t be done without covering the most important annual Neurology event in the world. We’re excited to provide clinicians the insights and online platform to get answers quickly that will help improve treatment options for their patients in the coming year.”

NeuroSeries Live delivers neurologists and other clinicians treating patients with neurological diseases a unique online learning platform that empowers clinical learners to questions and get immediate answers from experts about MS. The neurology channel of PlatformQ Health, NeuroSeries Live designs all its programs to be interactive throughout, so the physicians will be replying to questions throughout the presentation. Attendees can also give their opinion on best medical practices via in-session polls throughout the session.

The activity has been planned and implemented in accordance with requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Albert Einstein College of Medicine and Montefiore Medical Center and PlatformQ Health Education, LLC. The Albert Einstein College of Medicine and Montefiore Medical Center is accredited by the ACCME to provide continuing medical education for physicians.

Boston – April 12, 2016 – Survival and remission rates for multiple myeloma continue to climb as researchers and clinicians apply the latest research to patient treatment plans. With large conferences like ASCO still months away, it’s important to get timely updates on the latest treatment options for Multiple Myeloma.

Shaji Kumar, MD and David Dingli, MD, both Professors of Medicine, Hematology, at the Mayo Clinic in Rochester, Minnesota, will review the latest treatment practices at a one-hour online CME program hosted by OMedLive.com.

Attendees will learn the newest advances in treating relapsed/refractory multiple myeloma including:

The efficacy and safety of new and emerging agents, prognostic factors and patient-specific clinical criteria for treatment strategy selection, therapeutic implications of combination regimens involving emerging agents with currently available treatment options, timing of treatment initiation and genetic profiling based on disease characteristics and individual patient profiles.

“The therapy of multiple myeloma is evolving with the recent approval of several novel classes of agents: it is important that the role and impact of these exciting agents on the disease as well as specific toxicities are understood.” David Dingli, MD

We recommend this CME program for hematologists, oncologists, internal medicine physicians, family medicine/primary care physicians, and other clinicians who care for patients multiple myeloma, a rare form of cancer affecting about 0.7% of cancer cases overall.

The online CME session will take place April 13th, 11 am – Noon EST at OMedLive.com. This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Bristol-Myers Squibb, and Karyopharm Therapeutics, Inc.

CEO Robert Rosenbloom said, “we’re pleased to deliver this program on Multiple Myeloma ahead of the ASCO conference so clinicians can immediately expand their treatment options for patients. The life expectancy from the diagnosis of Multiple Myeloma increased from three months to four years over the past decade. We hope programs like this can increase it even further.”

One of the unique aspects of OMedLive’s online learning platform is the ability for attendees to ask direct questions to the experts about multiple myeloma. The physicians will be replying to questions throughout the presentation. Attendees can also give their opinion on best medical practices via polling questions throughout the session.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education. The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

Further information:

Boston – April 5, 2016 – Zika, already a problem in Puerto Rico and the U.S. Virgin Islands, is expected to reach the mainland U.S. as seasonal temperatures climb and the mosquito responsible for transmission becomes active in states such as Florida, Louisiana, and Texas.

The CDC will host a complimentary, online session, “A CDC Update for Clinicians on Zika Virus Disease.” Joanne Cono MD, ScM, the Director of Office of Science Quality, Office of the Director, Centers for Disease Control and Prevention will review the latest information for health care practitioners (HCPs) to implement in their practices. The session is scheduled for 1 pm – 2 pm EDT, April 6th.

At the conclusion of this session, participants will be able to:

  • Identify health effects related to Zika
  • Review the latest CDC Zika virus guidelines and recommendations for pregnant women, women of reproductive age, infants, and children
  • Understand clinical evaluation, diagnostic testing and treatment for Zika
  • Discuss opportunities with other clinicians and key community leaders to support prevention and control of Zika

The CDC describes the need for physicians and other health care practitioners to attend the session.

Zika virus is a mosquito-borne flavivirus transmitted primarily by Aedes species mosquitoes. Outbreaks of Zika have occurred in areas of Africa, Southeast Asia, the Pacific Islands, and the Americas. Because the Aedes species mosquitoes that can spread Zika virus are found throughout the world, it is likely that outbreaks will occur in new countries. Most people infected with Zika virus will not know they have the disease because they will not have symptoms. Join us for this educational activity to learn the latest information about Zika and to gain a better understanding of the role of clinicians in early recognition and reporting of suspected cases.

The CDC will deliver the session jointly with IDCareLive.com, an online educational site dedicated to infectious diseases. In addition, IDCareLive.com will live-tweet the event from @IDCareLive with the hashtag #ZikaChat.

HCPs can sign up for the event at: IDCareLive.com

Media Inquiries: Christian Rubio, Senior Director of Marketing, PlatformQ Health, Needham, MA.

Boston – January 12, 2016 – PlatformQ Health the parent company of NeuroSeriesLive and Primary Care Network will provide primary care clinicians, including those who specialize in internal medicine and family medicine, physician assistants, and nurse practitioners with an opportunity to hear migraine experts discuss the latest science around managing patients with acute migraine live via online video at no cost at NeuroSeriesLive. The event will be held on January 15, 2016, at 1:00 PM ET at NeuroSeriesLive.com. The program will mark the first event accredited and co-marketed as part of a new partnership with Primary Care Network. Primary Care Network is a leader in continuing medical education for primary care clinicians.

PlatformQ Health Executive Vice President David Murphy, “We are excited to collaborate with Primary Care Network to accredited and co-market our virtual events for US primary care clinicians. PlatformQ Health and Primary Care Network have a shared goal to provide health care providers with quality accredited online education that improves their knowledge, access to the latest science, top thought leaders and ultimately improve patient care.”

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Primary Care Network and PlatformQ Health Education, LLC. Primary Care Network is accredited by the ACCME to provide continuing medical education for physicians.

The program will feature Michael J. Marmura, MD, and Stephen D. Silberstein, MD, both of Jefferson Headache Center. Topics in the hour-long program will include: Rationale, timing and patient suitability for acute migraine treatment; benefits and limitations of various treatment options; use of prophylactic medication, and individualized acute treatment options. This activity is supported by an educational grant from Avanir Pharmaceuticals.

NeuroSeriesLive offers an effective way for clinicians to easily stay current on advances in care without leaving their office. There is no cost to register and watch any educational session at NeuroSeriesLive. Clinicians who attend live may take advantage of interactive capabilities like submitting questions to be addressed live online by presenting faculty and interactive polling.

To learn more and register at no cost for this live interactive video webcast, visit NeuroSeriesLive.com.

About NeuroSeriesLive

NeuroSeriesLive is a leader in online CME programs in Neurology treatment and science produced by PlatformQ Health, Inc. NeuroSeriesLive enables neurologists, internal medicine specialists, family care physicians and other healthcare practitioners interested in understanding and managing patients with neurologic disorders to learn, connect and interact in real time. NeuroSeriesLive offers virtual medical education at no cost and delivers all the benefits of a physical conference, with live presentations, real-time interactive Q&A, and an exhibit floor, all from the convenience of a computer. To learn more about NeuroSeriesLive, follow us via Twitter at @NeuroSeriesLive.

Contact

Mike Sweeney

msweeney@platformq.com

Boston – July 20, 2015 – PlatformQ Health, Inc., a leader in the online Continuing Medical Education (CME) field today announced its expansion into the patient education area. It will use its online platform to educate patients about the risks and treatment options for different medical conditions.

PlatformQ Health has partnered with the Joslin Diabetes Center and dLife.com to host an online patient education event on Diabetic Retinopathy on July 29, 2015, at 8:00 PM ET. The event will provide people with diabetes a unique opportunity to learn from the Joslin Diabetes Center experts about the risks and dangers of diabetic retinopathy for people with diabetes, as well as ways to protect their vision.

PlatformQ Health President & CEO Robert Rosenbloom, “Having used our unique platform successfully to educate thousands of clinicians, we’re excited to expand now to educating patients. The patient education programs will allow people to hear from and interact with medical experts, advocacy group leaders, and people like them to understand the risks and treatment options for different diseases. It’s a way for people to get access to this valuable content from anywhere – home, their workplace, or on their smartphone, wherever they may be.”

The event, made possible by an educational grant from Genentech, is part of a larger, multi-faceted program on diabetic retinopathy that also includes CME programs for retina specialists, ophthalmologists, and primary care physicians. The patient program will feature Timothy Murtha, MD, Deborah K. Schlossman, MD, and Jerry Cavallerano, OD, Ph.D. all of Joslin Diabetes Center. Participants will have the opportunity to interact directly with the faculty through polling and online Q&A.

To learn more and to attend at no cost for this interactive video webcast live or on-demand, visit www.DiabetesEyeHealth.com or follow us on Twitter @DiabetesEdLive.

About PlatformQ Health

PlatformQ Health is the leading provider of live online medical education events. Our unique education platform allows physicians and other healthcare professionals to connect online from any computer, learn about the latest treatment options, engage in real-time Q&A with top faculty and earn AMA PRA Category 1 Credits ™. Our solutions are a compliant alternative to “traditional” in-person events, which not only are more costly and time consuming but have a more limited reach.

Contact

Mike Sweeney

msweeney@platformq.com